UAB Digital Repository of Documents 10 records found  Search took 0.00 seconds. 
1.
17 p, 2.3 MB Combinatorial Blood Platelets-Derived circRNA and mRNA Signature for Early-Stage Lung Cancer Detection / D'Ambrosi, Silvia (Amsterdam UMC. University Medical Center) ; Giannoukakos, Stavros (Centro de Investigación Biomédica de la Universidad de Granada) ; Antunes-Ferreira, Mafalda (Amsterdam UMC. University Medical Center) ; Pedraz-Valdunciel, Carlos (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Bracht, Jillian (Hospital Universitari Dexeus - Grup Quirónsalud) ; Potie, Nicolas (Centro de Investigación Biomédica de la Universidad de Granada) ; Giménez-Capitán, Ana (Hospital Universitari Dexeus - Grup Quirónsalud) ; Hackenberg, Michael (Centro de Investigación Biomédica de la Universidad de Granada) ; Fernandez Hilario, Alberto (Universidad de Granada) ; Molina-Vila, Miguel Ángel (Hospital Universitari Dexeus - Grup Quirónsalud) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Würdinger, Thomas (Amsterdam UMC. University Medical Center) ; Koppers-Lalic, Danijela (Leiden University) ; Universitat Autònoma de Barcelona
Despite the diversity of liquid biopsy transcriptomic repertoire, numerous studies often exploit only a single RNA type signature for diagnostic biomarker potential. This frequently results in insufficient sensitivity and specificity necessary to reach diagnostic utility. [...]
2023 - 10.3390/ijms24054881
International journal of molecular sciences, Vol. 24 (march 2023)  
2.
10 p, 654.4 KB Multiplex Detection of Clinically Relevant Mutations in Liquid Biopsies of Cancer Patients Using a Hybridization-Based Platform / Giménez-Capitán, Ana (Grup Quirónsalud (Barcelona, Catalunya)) ; Bracht, Jillian (Universitat Autònoma de Barcelona) ; García Mosquera, Juan José (Grup Quirónsalud (Barcelona, Catalunya)) ; Jordana-Ariza, Núria (Grup Quirónsalud (Barcelona, Catalunya)) ; García, Beatriz (Grup Quirónsalud (Barcelona, Catalunya)) ; Garzón Ibáñez, Mónica (Grup Quirónsalud (Barcelona, Catalunya)) ; Mayo-De-Las-Casas, Clara (Grup Quirónsalud (Barcelona, Catalunya)) ; Viteri, Santiago (Grup Quirónsalud (Barcelona, Catalunya)) ; Martínez-Bueno, Alejandro (Grup Quirónsalud (Barcelona, Catalunya)) ; Aguilar-Hernández, Andrés (Grup Quirónsalud (Barcelona, Catalunya)) ; Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ; Johnson, Eric (NanoString Technologies) ; Huang, Chun-Ying (NanoString Technologies) ; Gerlach, Jay L. (NanoString Technologies) ; Warren, Sarah (NanoString Technologies) ; Beechem, Joseph M. (NanoString Technologies) ; Teixidó, Cristina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Reguart, Noemi (Hospital Clínic i Provincial de Barcelona) ; Molina-Vila, Miguel Ángel. (Grup Quirónsalud (Barcelona, Catalunya))
BACKGROUND: With the advent of precision oncology, liquid biopsies are quickly gaining acceptance in the clinical setting. However, in some cases, the amount of DNA isolated is insufficient for Next-Generation Sequencing (NGS) analysis. [...]
2021 - 10.1093/clinchem/hvaa248
Clinical Chemistry, Vol. 67 Núm. 3 (january 2021) , p. 554-563  
3.
8 p, 334.2 KB Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Non-Small-Cell Lung Cancer : Retrospective Testing of Specimens from the EURTAC Trial / Benlloch, Susana (Pangaea Biotech) ; Botero, Maria Luisa (Pangaea Biotech) ; Beltran-Alamillo, Jordi (Pangaea Biotech) ; Mayo, Clara (Pangaea Biotech) ; Giménez-Capitán, Ana (Pangaea Biotech) ; de Aguirre, Itziar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Queralt, C (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ramón y Cajal, Santiago (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ; Klughammer, Barbara (F. Hoffmann-La Roche, Basel) ; Schlegel, Mariette (F. Hoffmann-La Roche, Basel) ; Bordogna, Walter (F. Hoffmann-La Roche, Basel) ; Chen, David (Genentech, South San Francisco, California) ; Zhang, Guili (Roche Molecular Systems, Pleasanton, California) ; Kovach, Barbara (Roche Molecular Systems, Pleasanton, California) ; Shieh, Felice (Roche Molecular Systems, Pleasanton, California) ; Palma, John F. (Roche Molecular Systems, Pleasanton, California) ; Wu, Lin (Roche Molecular Systems, Pleasanton, California) ; Lawrence, H. Jeffrey (Roche Molecular Systems, Pleasanton, California) ; Taron, Miquel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
The EURTAC trial demonstrated that the tyrosine kinase inhibitor (TKI) erlotinib was superior to chemotherapy as first-line therapy for advanced non-small cell lung cancers (NSCLC) that harbor EGFR activating mutations in a predominantly Caucasian population. [...]
2014 - 10.1371/journal.pone.0089518
PloS one, Vol. 9 (february 2014)  
4.
12 p, 4.7 MB Analysis of extracellular vesicle mRNA derived from plasma using the nCounter platform / Bracht, Jillian (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Giménez-Capitán, Ana (Quirón Dexeus University Hospital. Pangaea Oncology, Laboratory of Oncology) ; Huang, Chung-Ying (NanoString Technologies, Seattle, WA USA) ; Potie, Nicolas (Biotechnology Institute, Centro de Investigacion Biomedica, PTS. Bioinformatics Laboratory) ; Pedraz-Valdunciel, Carlos (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Warren, Sarah (NanoString Technologies, Seattle, WA USA) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Molina-Vila, Miguel Ángel (Quirón Dexeus University Hospital. Pangaea Oncology, Laboratory of Oncology)
Extracellular vesicles (EVs) are double-layered phospholipid membrane vesicles that are released by most cells and can mediate intercellular communication through their RNA cargo. In this study, we tested if the NanoString nCounter platform can be used for the analysis of EV-mRNA. [...]
2021 - 10.1038/s41598-021-83132-0
Scientific reports, Vol. 11 (february 2021)  
5.
11 p, 2.1 MB Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma / Ito, Masaoki (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Codony-Servat, Jordi (Institut Universitari Dexeus) ; Giménez-Capitán, Ana (Institut Universitari Dexeus) ; Serra-Mitjans, Mireia (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Pérez-Ochoa, Francisco (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Llige, David (Institut Germans Trias i Pujol) ; Chaib, Imane (Institut Germans Trias i Pujol) ; Rami-Porta, Ramon (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Obiols, Carme (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Call, Sergi (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ; Iglesias, Manuela (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Belda, José (Belda Sanchis) (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Tarroch-Sarasa, Xavier (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Karachaliou, Niki (Institut Universitari Dexeus) ; Molina-Vila, Miguel Ángel (Institut Universitari Dexeus) ; Okada, Morihito (Hiroshima University. Department of Surgical Oncology) ; Rosell, Rafael (Institut Germans Trias i Pujol)
EGFR mutation-positive lung adenocarcinoma (LUAD) displays impaired phosphorylation of ERK and Src-homology 2 domain-containing phosphatase 2 (SHP2) in comparison with EGFR wild-type LUADs. We hypothesize that SHP2 expression could be predictive in patients positive with resected EGFR mutation versus patients with EGFR wild-type LUAD. [...]
2020 - 10.1016/j.jtocrr.2020.100084
JTO Clinical and Research Reports, Vol. 1 Núm. 4 (august 2020)  
6.
14 p, 2.2 MB Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer / Aguado, Cristina (Quirón Dexeus University Hospital) ; Teixidó, Cristina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Román, Ruth (Quirón Dexeus University Hospital) ; Reyes, Roxana (Hospital Clínic i Provincial de Barcelona) ; Giménez-Capitán, Ana (Quirón Dexeus University Hospital) ; Marin, Elba (Hospital Clínic i Provincial de Barcelona) ; Cabrera, Carlos (Grup Quirónsalud (Barcelona, Catalunya)) ; Viñolas, Nuria (Hospital Clínic i Provincial de Barcelona) ; Castillo, Sergi (Hospital General de Granollers) ; Muñoz, Silvia (Hospital General de Granollers) ; Arcocha, Ainara (Hospital Clínic i Provincial de Barcelona) ; López Vilaró, Laura (Institut d'Investigació Biomèdica Sant Pau) ; Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ; Aldeguer, Erika (Quirón Dexeus University Hospital) ; Rodríguez, Sonia (Quirón Dexeus University Hospital) ; Moya, Irene (Grup Quirónsalud (Barcelona, Catalunya)) ; Viteri, Santiago (Quiron Salud Group) ; Cardona Zorrilla, Andrés Felipe (Clínica del Country) ; Palmero, Ramon (L'Hospitalet) ; Sainz, Cristina (Centro de Investigación Biomédica en Red de Cáncer) ; Mesa-Guzmán, Miguel (Universidad Pública de Navarra) ; Lozano, Maria D. (Universidad Pública de Navarra) ; Aguilar-Hernández, Andrés (Grup Quirónsalud (Barcelona, Catalunya)) ; Martínez-Bueno, Alejandro (Grup Quirónsalud (Barcelona, Catalunya)) ; González-Cao, María (Grup Quirónsalud (Barcelona, Catalunya)) ; Gonzalvo, Elena (Hospital Clínic i Provincial de Barcelona) ; Leenders, William P. J. (Radboud Institute for Molecular Life Sciences) ; Rosell, Rafael (Universitat Autònoma de Barcelona. Departament de Medicina) ; Montuenga, Luis M. (Universidad Pública de Navarra) ; Prat, Aleix (Hospital Clínic i Provincial de Barcelona) ; Molina-Vila, Miguel Ángel (Quirón Dexeus University Hospital) ; Reguart, Noemi (Hospital Clínic i Provincial de Barcelona)
We studied MET alterations in 474 advanced non-small-cell lung cancer (NSCLC) patients by nCounter, an RNA-based technique. We identified 3% with MET Δex14 mRNA and 3. 5% with very-high MET mRNA expression, a surrogate of MET amplification. [...]
2020 - 10.1002/1878-0261.12861
Molecular Oncology, Vol. 15 (december 2020) , p. 350-363  
7.
6 p, 538.4 KB Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer / Bonanno, Laura (Medical Oncology 2 Unit, Istituto Oncologico Veneto I.R.C.C.S, Via Gattamelata 64, 35128 Padova, Italy) ; Costa, Carla (Pangaea Biotech (Barcelona, Catalunya)) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Sanchez, Jose-Javier (Universidad Autónoma de Madrid) ; Rodriguez, Ignacio (Universitat Autònoma de Barcelona. Institut Universitari Dexeus) ; Giménez-Capitán, Ana (Pangaea Biotech (Barcelona, Catalunya)) ; Molina-Vila, Miquel Angel (Pangaea Biotech (Barcelona, Catalunya)) ; Vergnenegre, Alain (Hospital du Cluzeau, 23, rue Larey, Limoges, France) ; Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Favaretto, Adolfo (Medical Oncology 2 Unit, Istituto Oncologico Veneto I.R.C.C.S, Via Gattamelata 64, 35128 Padova, Italy) ; Rugge, Massimo (Cytology and Pathology, Università degli Studi di Padova, Via Gabelli 61, Padova, Italy) ; Pallares, Cinta (Institut d'Investigació Biomèdica Sant Pau) ; Taron, Miquel (Universitat Autònoma de Barcelona. Institut Universitari Dexeus) ; Rosell, Rafael (Universitat Autònoma de Barcelona. Institut Universitari Dexeus) ; Universitat Autònoma de Barcelona
BRCA1 is a main component of homologous recombination and induces resistance to platinum in preclinical models. It has been studied as a potential predictive marker in lung cancer. Several proteins modulate the function of BRCA1. [...]
2016 - 10.1186/s12885-016-2339-5
BMC Cancer, Vol. 16 (may 2016)  
8.
7 p, 627.6 KB Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer / Wei, J. (Clinical Cancer Institute of Nanjing University) ; Costa, C. (Institut Dexeus) ; Shen, J. (Clinical Cancer Institute of Nanjing University) ; Yu, L. (TClinical Cancer Institute of Nanjing University) ; Sanchez, J. J. (Universidad Autónoma de Madrid. Departamento de Medicina Preventiva y Salud Pública) ; Qian, X (Clinical Cancer Institute of Nanjing University) ; Sun, X (Clinical Cancer Institute of Nanjing University) ; Zou, Z. (Clinical Cancer Institute of Nanjing University) ; Giménez-Capitán, Ana (Institut Dexeus) ; Yue, G. (Clinical Cancer Institute of Nanjing University) ; Guan, W. (Nanjing University. Department of General Surgery) ; Rosell, R. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Liu, B. (Clinical Cancer Institute of Nanjing University) ; Universitat Autònoma de Barcelona
Breast cancer susceptibility gene 1 (BRCA1) expression differentially affects outcome to platinum- and taxane-based chemotherapy. Mediator of DNA damage checkpoint protein 1 (MDC1), p53-binding protein 1 (53BP1), multiple myeloma SET domain (MMSET) and ubiquitin-conjugating enzyme 9 (UBC9) are involved in DNA repair and could modify the BRCA1 predictive model. [...]
2014 - 10.1038/bjc.2014.231
British Journal of Cancer, Vol. 110 (05 2014) , p. 2662-2668  
9.
9 p, 287.7 KB The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer / Margelí, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Cirauqui, Beatriz (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Castellà Fernández, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Tapia, Gustavo (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ; Costa, Carla (Institut Universitari Dexeus) ; Giménez-Capitán, Ana (Institut Universitari Dexeus) ; Barnadas i Molins, Agustí (Institut d'Investigació Biomèdica Sant Pau) ; Ronco, Maria Sanchez (Universidad de Alcalá) ; Benlloch, Susana (Institut Universitari Dexeus) ; Taron, Miquel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
A fraction of sporadic breast cancers has low BRCA1 expression. BRCA1 mutation carriers are more likely to achieve a pathological complete response with DNA-damage-based chemotherapy compared to non-mutation carriers. [...]
2010 - 10.1371/journal.pone.0009499
PloS one, Vol. 5 (3 2010)  
10.
12 p, 942.4 KB BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer / Karachaliou, Niki (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Codony-Servat, Jordi (Pangaea Biotech (Barcelona, Catalunya)) ; Teixidó, Cristina (Pangaea Biotech (Barcelona, Catalunya)) ; Pilotto, Sara (University of Verona (Itàlia)) ; Drozdowskyj, Ana (Pivotal (Madrid)) ; Codony Servat, Carles (Pangaea Biotech (Barcelona, Catalunya)) ; Giménez-Capitán, Ana (Pangaea Biotech (Barcelona, Catalunya)) ; Molina-Vila, Miguel Ángel (Pangaea Biotech (Barcelona, Catalunya)) ; Bertrán-Alamillo, Jordi (Pangaea Biotech (Barcelona, Catalunya)) ; Gervais, Radj (Centre François Baclesse (Caen, França)) ; Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; García-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ; Viteri, Santiago (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; González-Cao, María (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Morales-Espinosa, Daniela (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Verlicchi, Alberto (Ospedale Santa Maria delle Croci (Ravenna, Itàlia)) ; Crisetti, Elisabetta (Institute of Respiratory Diseases. University of Foggia (Itàlia)) ; Chaib, Imane (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Santarpia, Mariacarmela (Human Pathology Department. University of Messina (Itàlia)) ; Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Bosch-Barrera, J (Hospital Universitari de Girona Doctor Josep Trueta) ; Cardona Zorrilla, Andrés Felipe (Instituto de Oncología de Clínica del Country (Bogotá, Colòmbia)) ; De Marinis, Filippo (Istituto Europeo di Oncologia (Milà, Itàlia)) ; López-Vivanco, Guillermo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Sánchez, José Miguel (Hospital Universitario de la Princesa (Madrid)) ; Vergnenegre, Alain (Hôpital du Cluzeau (Limoges, França)) ; Sánchez Hernández, José Javier (Universidad Autónoma de Nuevo León (Mèxic)) ; Sperduti, Isabella (Istituto Regina Elena Cancer Institute (Roma, Itàlia)) ; Bria, Emilio (University of Verona (Itàlia)) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Abstract. BIM is a proapoptotic protein that initiates apoptosis triggered by EGFR tyrosine kinase inhibitors (TKI). mTOR negatively regulates apoptosis and may influence response to EGFR TKI. We examined mRNA expression of BIM and MTOR in 57 patients with EGFR-mutant NSCLC from the EURTAC trial. [...]
2015 - 10.1038/srep17499
Scientific reports, Vol. 7 (December 2015)  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.